Drug intelligence / Profile preview

Prospekta-VET

Development stage
Unknown
Lead developer
Materia Medica Holding
Modality
Antibody-Based Therapeutics
Administration
Oral
01

Overview

**Prospekta-VET** (formerly known as **Anoten**) is an approved veterinary neuroimmunobiological drug developed by Materia Medica Lifesciences for dogs and cats. It is formulated as an oral powder containing affinity-purified, modified antibodies to the brain-specific S-100 protein in a release-active form. Prospekta-VET is indicated for the normalization of animal behavior, alleviation of stress and anxiety symptoms, and facilitation of adaptation to new environments, transportation, grooming, or veterinary interventions. By modulating the functional activity of the S-100 protein, the drug regulates synaptic transmission, neuronal plasticity, and the balance between excitatory and inhibitory neurotransmitter systems in the central nervous system, providing anxiolytic, nootropic, and neuroprotective effects without causing sedation or muscle relaxation.

Brand names
AnotenProspekta-VET
Other names
affinity-purified modified antibodies to brain-specific S-100 proteinantibodies to brain-specific S-100 proteinantibodies to S100 proteinrelease-active antibodies to brain-specific S-100 proteinrelease-active antibodies to S-100 protein
02

Targets

S100B (S100 Calcium-Binding Protein B)

Beyond the preview

Go deeper on Prospekta-VET.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Prospekta-VET.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call